BR112021020883A2 - Formas sólidas de um inibidor de glyt1 - Google Patents
Formas sólidas de um inibidor de glyt1Info
- Publication number
- BR112021020883A2 BR112021020883A2 BR112021020883A BR112021020883A BR112021020883A2 BR 112021020883 A2 BR112021020883 A2 BR 112021020883A2 BR 112021020883 A BR112021020883 A BR 112021020883A BR 112021020883 A BR112021020883 A BR 112021020883A BR 112021020883 A2 BR112021020883 A2 BR 112021020883A2
- Authority
- BR
- Brazil
- Prior art keywords
- solid forms
- inhibitor
- glyt1
- glyt1 inhibitor
- relates
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 5
- 229940123454 Glucose transporter 1 inhibitor Drugs 0.000 title abstract 2
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 1
- 229940088352 Glycine transporter inhibitor Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841401P | 2019-05-01 | 2019-05-01 | |
| PCT/US2020/030580 WO2020223419A1 (en) | 2019-05-01 | 2020-04-30 | Solid forms of a glyt1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020883A2 true BR112021020883A2 (pt) | 2022-04-19 |
Family
ID=70740812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020883A BR112021020883A2 (pt) | 2019-05-01 | 2020-04-30 | Formas sólidas de um inibidor de glyt1 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11447474B2 (https=) |
| EP (1) | EP3962911A1 (https=) |
| JP (2) | JP7513349B2 (https=) |
| KR (1) | KR20220004174A (https=) |
| CN (1) | CN113784966B (https=) |
| AR (1) | AR118839A1 (https=) |
| AU (1) | AU2020266566B2 (https=) |
| BR (1) | BR112021020883A2 (https=) |
| CA (1) | CA3138288A1 (https=) |
| CL (2) | CL2021002837A1 (https=) |
| CO (1) | CO2021014260A2 (https=) |
| CR (1) | CR20210545A (https=) |
| DO (1) | DOP2021000224A (https=) |
| EA (1) | EA202192925A1 (https=) |
| EC (1) | ECSP21082195A (https=) |
| IL (1) | IL287630A (https=) |
| JO (1) | JOP20210295A1 (https=) |
| MA (1) | MA55801A (https=) |
| MX (1) | MX2021013341A (https=) |
| PE (1) | PE20212263A1 (https=) |
| PH (1) | PH12021552741A1 (https=) |
| SG (1) | SG11202111972YA (https=) |
| TW (1) | TW202106680A (https=) |
| UA (1) | UA129159C2 (https=) |
| WO (1) | WO2020223419A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7930336B2 (en) | 2006-12-05 | 2011-04-19 | Altera Corporation | Large multiplier for programmable logic device |
| EA202192925A1 (ru) * | 2019-05-01 | 2022-03-23 | Бёрингер Ингельхайм Интернациональ Гмбх | Твердые формы ингибитора glyt1 |
| US11813257B2 (en) | 2020-01-09 | 2023-11-14 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| MX2023001818A (es) * | 2020-08-13 | 2023-03-13 | Boehringer Ingelheim Int | Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia. |
| IL301829A (en) | 2020-10-13 | 2023-06-01 | Boehringer Ingelheim Int | Process of reworking |
| WO2025140479A1 (zh) * | 2023-12-29 | 2025-07-03 | 苏州科睿思制药有限公司 | Iclepertin的晶型及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL65843A (en) * | 1977-08-11 | 1986-12-31 | American Cyanamid Co | Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type |
| RS20060190A (sr) * | 2003-10-14 | 2008-08-07 | Pfizer Products Inc., | Biciklični /3.1.0/ derivati kao inhibitori transportera glicina |
| CA2745690A1 (en) * | 2008-12-04 | 2010-06-10 | Evgeny Zlotinikov | Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative |
| EP2381941A4 (en) * | 2008-12-29 | 2012-08-01 | Univ Vanderbilt | 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US9012489B2 (en) | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| IL270155B (en) * | 2017-04-27 | 2022-07-01 | Takeda Pharmaceuticals Co | Heterocyclic compound |
| EA202192925A1 (ru) * | 2019-05-01 | 2022-03-23 | Бёрингер Ингельхайм Интернациональ Гмбх | Твердые формы ингибитора glyt1 |
| MX2023001818A (es) * | 2020-08-13 | 2023-03-13 | Boehringer Ingelheim Int | Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia. |
| IL301829A (en) * | 2020-10-13 | 2023-06-01 | Boehringer Ingelheim Int | Process of reworking |
-
2020
- 2020-04-30 EA EA202192925A patent/EA202192925A1/ru unknown
- 2020-04-30 TW TW109114685A patent/TW202106680A/zh unknown
- 2020-04-30 PE PE2021001800A patent/PE20212263A1/es unknown
- 2020-04-30 EP EP20726654.5A patent/EP3962911A1/en active Pending
- 2020-04-30 DO DO2021000224A patent/DOP2021000224A/es unknown
- 2020-04-30 WO PCT/US2020/030580 patent/WO2020223419A1/en not_active Ceased
- 2020-04-30 AU AU2020266566A patent/AU2020266566B2/en active Active
- 2020-04-30 PH PH1/2021/552741A patent/PH12021552741A1/en unknown
- 2020-04-30 KR KR1020217039503A patent/KR20220004174A/ko not_active Ceased
- 2020-04-30 UA UAA202106566A patent/UA129159C2/uk unknown
- 2020-04-30 CA CA3138288A patent/CA3138288A1/en active Pending
- 2020-04-30 JP JP2021563717A patent/JP7513349B2/ja active Active
- 2020-04-30 SG SG11202111972YA patent/SG11202111972YA/en unknown
- 2020-04-30 JO JOP/2021/0295A patent/JOP20210295A1/ar unknown
- 2020-04-30 CN CN202080032902.7A patent/CN113784966B/zh active Active
- 2020-04-30 CR CR20210545A patent/CR20210545A/es unknown
- 2020-04-30 US US16/862,608 patent/US11447474B2/en active Active
- 2020-04-30 BR BR112021020883A patent/BR112021020883A2/pt unknown
- 2020-04-30 AR ARP200101242A patent/AR118839A1/es unknown
- 2020-04-30 MA MA055801A patent/MA55801A/fr unknown
- 2020-04-30 MX MX2021013341A patent/MX2021013341A/es unknown
-
2021
- 2021-10-26 CO CONC2021/0014260A patent/CO2021014260A2/es unknown
- 2021-10-27 IL IL287630A patent/IL287630A/en unknown
- 2021-10-28 CL CL2021002837A patent/CL2021002837A1/es unknown
- 2021-11-17 EC ECSENADI202182195A patent/ECSP21082195A/es unknown
-
2022
- 2022-06-27 US US17/849,935 patent/US20220332710A1/en not_active Abandoned
-
2024
- 2024-03-21 CL CL2024000829A patent/CL2024000829A1/es unknown
- 2024-05-02 JP JP2024074707A patent/JP7714727B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021020883A2 (pt) | Formas sólidas de um inibidor de glyt1 | |
| CY1124486T1 (el) | Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου | |
| JOP20220131A1 (ar) | مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة | |
| PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| JOP20200277B1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| EP4674479A3 (en) | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
| MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| PH12020550494A1 (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors | |
| BR112017001093A2 (pt) | formulação aquosa compreendendo paracetamol e ibuprofeno | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| MX2020008125A (es) | Composiciones que comprenden berberina. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
| BR112017028616A2 (pt) | acentuador de inibidores de homólogo de zeste 2 | |
| BR112022008183A2 (pt) | Formas de sal de um receptor de c5a de componente do complemento | |
| BR112022007718A2 (pt) | Composição farmacêutica, e, métodos de tratamento de um sujeito em necessidade e para produção de uma composição farmacêutica sólida | |
| MX420767B (es) | Proteina de union al factor h modificada | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| PH12018000227B1 (en) | A pharmaceutical composition for improving or preventing progression of chronic kidney disease | |
| CO2021004612A2 (es) | Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento | |
| JOP20220097A1 (ar) | كريزانليزوماب يحتوي على صياغات اجسام مضادة |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |